301 PENOBSCOT DR REDWOOD CITY, CA 94063 Get Directions
In addition to developing products to address new cancer areas, we continually look to expand the clinical utility and addressable patient populations for our existing Oncotype DX tests. These development efforts may lead to a variety of possible new products covering various treatment decisions, including:
Screening and prevention
Early disease diagnosis
Adjuvant disease diagnosis
Metastatic treatment selection
Potential new products may address a specific clinical need or guide a targeted therapy decision and may also leverage our NGS (next generation sequencing) capabilities to expand our product opportunities.